Temazepam (Restoril, Sandoz Pharmaceuticals)

Drug Intelligence & Clinical Pharmacy
J C McElnayB Alexander

Abstract

Temazepam is a benzodiazepine derivative indicated for the treatment of insomnia. Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours. Sleep laboratory studies have demonstrated improvements in all sleep parameters except sleep onset latency. Clinically, patients report improvements in all sleep parameters including sleep onset latency. The efficacy of temazepam compares favorably with barbiturates, glutethimide, nitrazepam, lorazepam, oxazepam, and flurazepam. It has not been compared with diazepam in the clinical setting. Side effects include drowsiness, dizziness, and lethargy. The incidence of hangover effects from 15- and 30-mg doses is relatively low. Temazepam has no proven advantages over other benzodiazepine hypnotics. The major issues that need further clarification include temazepam's sleep induction properties and the relative incidence of hangover and rebound insomnia when compared with longer-acting benzodiazepines.

References

May 1, 1976·Clinical Pharmacology and Therapeutics·A KalesJ D Kales
May 1, 1979·British Journal of Clinical Pharmacology·A N Nicholson, B M Stone
Jan 1, 1979·The Journal of International Medical Research·L K Fowler
Jan 1, 1979·British Journal of Clinical Pharmacology·H J Schwarz
Jan 1, 1979·British Journal of Clinical Pharmacology·T RothM Kaffeman
Jan 1, 1979·British Journal of Clinical Pharmacology·M M MitlerW C Dement
Jan 1, 1979·British Journal of Clinical Pharmacology·W A Heffron, P Roth
Jan 1, 1979·British Journal of Clinical Pharmacology·J M Fillingim
Sep 1, 1975·Clinical Pharmacology and Therapeutics·A KalesM B Scharf
Aug 1, 1977·The Journal of Physiology·T Kondo, D F Magee
Feb 1, 1978·Journal of Clinical Pharmacology·E O BixlerJ D Kales
Oct 1, 1978·British Journal of Clinical Pharmacology·C H Clarke, A N Nicholson
Jan 1, 1979·British Journal of Clinical Pharmacology·A N Nicholson
Dec 16, 1977·European Journal of Clinical Pharmacology·L M FuccellaG Tognoni
Jan 1, 1978·The Journal of International Medical Research·R S Middleton
Jan 1, 1976·The Journal of International Medical Research·R G Priest, Z A Rizvi
Jan 27, 1977·The New England Journal of Medicine·S L HayesR F Palmer
Jan 1, 1976·The Journal of International Medical Research·A PinesJ F Rooney
Aug 23, 1974·European Journal of Clinical Pharmacology·M LinnoilaM Maki
Jun 1, 1980·British Journal of Clinical Pharmacology·T V Harry, A N Latham
Jan 1, 1980·The Journal of International Medical Research·L K Fowler
Sep 1, 1980·British Journal of Anaesthesia·B J PleuvryM E Dodson
Jun 6, 1981·British Medical Journal·L Ratna
Jan 1, 1981·European Journal of Clinical Pharmacology·W Lehmann, B Liljenberg
Oct 1, 1981·Journal of Pharmaceutical Sciences·M DivollR I Shader
May 1, 1980·The New England Journal of Medicine·U Klotz, I Reimann
Aug 1, 1980·Annals of Internal Medicine·P V DesmondK V Speeg
Aug 1, 1976·British Journal of Clinical Pharmacology·A N Nicholson, B M Stone

Related Concepts

Metazoa
Drug Interactions
Half-Life
Subwakefullness Syndrome
Pfizer Brand 1 of Temazepam
Anti-Anxiety Effect

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Systemic Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis is a rare rheumatic disease that affects children. Symptoms include joint pain, but also fevers and skin rashes. Here is the latest on this disease.

Chromatin Regulation and Circadian Clocks

The circadian clock plays an important role in regulating transcriptional dynamics through changes in chromatin folding and remodelling. Discover the latest research on Chromatin Regulation and Circadian Clocks here.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Pontocerebellar Hypoplasia

Pontocerebellar hypoplasias are a group of neurodegenerative autosomal recessive disorders with prenatal onset, atrophy or hypoplasia of the cerebellum, hypoplasia of the ventral pons, microcephaly, variable neocortical atrophy and severe mental and motor impairments. Here is the latest research on pontocerebellar hypoplasia.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.

Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease that occurs in individuals that suffer repetitive brain trauma. Discover the latest research on traumatic encephalopathy here.